Over time, clinical trials for vaccines against Covid-19 are gradually being updated, and one of these is the Moderna trial, which indicated that 90% effective against disease And 95 percent against severe forms of the disease, according to the US biotechnology company announced in the new published results, slightly lower than in a previous clinical trial.
The The data comes from a phase 3 clinical trial More than 30,000 people participated in it in the United States. The efficacy is just below the 94.1% reported in a large clinical trial published in New England Journal of Medicine in December.
Moderna did not state in its statement whether the decrease in effectiveness was due to the emergence of new variants, pero biotechnology company You are working on two modified versions of your vaccine, Variant-specific, with encouraging results in mice, but not yet subject to peer review.
“The new preclinical data about our candidate vaccine for a particular variant gives us confidence in our ability to anticipate the emergence of new variants,” praised Stephane Bancel, President of Moderna.
As of April 12, Moderna said it had shipped 132 million doses of the coronavirus vaccine worldwide, including 117 million in the United States.
It was still on track to provide Americans with an additional 100 million doses by the end of May, and another 100 million by the end of June.
The company’s clinical trial of adolescents between the ages of 12 and 17 has about 3,000 participants in the U.S.